Dividend King Growth Giant: J&J Faces Lilly Challenge
Johnson & Johnson and Eli Lilly reported contrasting Q1 2026 results, pitting a durable, dividend-focused giant again...
Which Credit Cards Offer Cash Rewards No Annual Fee
Discover credit cards that provide cash rewards without annual fees. Make your spending count!
26,108 articles
Crinetics Director Sells 5,000 Shares: Key Takeaways
A Crinetics director sells 5,000 shares as the stock dips. This guide breaks down what insider moves really mean for ...
MoonLake Immunotherapeutics Trims Stake: Investor Watch
When a high-level insider trims a stake, it can spark questions about a company’s near-term prospects. This article b...
Meta CoreWeave: Despite 2032 Pact, Compute Threat Persists
Meta Platforms and CoreWeave reported sharply different Q1 2026 results, highlighting Meta’s cash-flow machine and Co...
Micron Could Be Cheap If AI Continues Scaling From Here
Micron Technology rides a surge in AI memory demand, delivering stronger margins and robust cash flow. As the company...
Four REITs Fund This Income ETF's Distributions Now
The Columbia Research Enhanced Real Estate ETF (CRED) yields about 3.6% via pass-through REIT dividends. The fund’s i...
Astera Labs Chairman Manuel: Should You Sell ALAB?
A high-profile insider move has many ALAB investors wondering what comes next. This article breaks down the $60.5 mil...
Is Critical Metals Stock Going to Zero? Real Miner Prospects
Hyped up rare-earth plays attract attention, but many stumble before they mine. This guide breaks down how to assess ...
Massive News Intel Stock Sparks Market Momentum Today
Intel reveals a slate of high-impact partnerships and capacity expansions that could redefine its role in AI and clou...
Prediction: Tesla Stock Will Reach a Price in July
A controversial July forecast has investors buzzing: prediction: tesla stock will swing sharply. This article breaks ...
Turning Point Brands Stock Shines: A Thursday Rally
Turning Point Brands stock captured attention with a double-digit sales lift and solid earnings signs that stunned ma...
Since 2024: Glaring Reality Keeps AbbVie on Hold
AbbVie’s stock has climbed since 2024, yet a stubborn balance sheet and looming biosimilar erosion create a cautious ...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status